Introduction: Ulcerative colitis (UC) is a chronic relapsing disorder of the colonic tract. Dysregulated innate and adaptive immune pathways contribute to intestinal inflammation in IBD, and cytokines, including IL-12 and IL-23, play a key role. The blockade of both IL-12 and IL-23 may have an impact on different pathways of inflammation and could be effective for the treatment of inflammatory bowel diseases.Ustekinumab is a fully human IgG1κ monoclonal antibody which binds to the shared p40 protein subunit of IL-12 and -23. It is currently approved for several immune-mediated diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease, and has shown promising results in UC.Areas covered: A review of the literature was performed to understand several aspects including the role of IL-12 and -23 in UC, the potential therapeutic role of ustekinumab in inflammatory bowel disease, and the positioning of ustekinumab in the therapeutic algorithm of UC, based on extrapolated data from available randomized clinical trials.Expert opinion: Ustekinumab is effective and safe in UC, and shows potential advantages compared to other drugs in moderate-to-severe UC.

中文翻译：

---

将ustekinumab定位于中度至重度溃疡性结肠炎：刚开始接受治疗。

简介：溃疡性结肠炎（UC）是结肠的一种慢性复发性疾病。先天性和适应性免疫途径失调导致了IBD的肠道炎症，而包括IL-12和IL-23在内的细胞因子起着关键作用。IL-12和IL-23的阻滞均可能影响不同的炎症途径，并可能有效地治疗炎症性肠病。Ustekinumab是一种完全人源的IgG1κ单克隆抗体，可与IL的共享p40蛋白亚基结合-12和-23。目前已被批准用于多种免疫介导的疾病，例如中度至重度斑块状牛皮癣，牛皮癣性关节炎和克罗恩氏病，并且在UC中显示出令人鼓舞的结果。研究范围：对文献进行了综述，以了解包括作用在内的几个方面UC中的IL-12和-23